- Home
- EDIT vs HFRO Comparison
EDIT vs HFRO Comparison
Compare EDIT & HFRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EDIT | HFRO |
|---|---|---|
| Founded | 2013 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 310.9M | 344.0M |
| IPO Year | 2016 | N/A |
Fundamental Metrics
Financial Performance| Metric | EDIT | HFRO |
|---|---|---|
| Price | $2.91 | $6.15 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $5.30 | N/A |
| AVG Volume (30 Days) | ★ 1.3M | 102.5K |
| Earning Date | 05-11-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 8.87% |
| EPS Growth | ★ 37.50 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $31,937,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 132.64 | N/A |
| 52 Week Low | $1.43 | $4.94 |
| 52 Week High | $4.54 | $6.83 |
Technical Indicators
Market Signals| Indicator | EDIT | HFRO |
|---|---|---|
| Relative Strength Index (RSI) | 48.07 | 54.33 |
| Support Level | $2.77 | $6.12 |
| Resistance Level | $3.17 | $6.24 |
| Average True Range (ATR) | 0.22 | 0.14 |
| MACD | -0.04 | -0.01 |
| Stochastic Oscillator | 28.00 | 16.13 |
Price Performance
Historical ComparisonAbout EDIT Editas Medicine Inc.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary gene editing platform based on CRISPR technology and continues to expand its capabilities. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1). The company has a single operating segment, which is the business of developing and commercializing gene editing technology.
About HFRO Highland Opportunities and Income Fund of Beneficial Interest
Highland Opportunities and Income Fund is a non-diversified, closed-end management investment company. Its investment objective is to Income Fund seeks growth of capital along with income. It focuses on making investments in real estate securities, including Reits, secured and unsecured fixed-rate loans and corporate bonds, mezzanine securities, structured products, convertible and preferred securities and equities (public and private), and floating rate securities.